alloimmunization

Alloimmunization occurs when an individual's immune system is exposed to alloantigens (antigens from a genetically distinct individual of the same species) and mounts a humoral response, producing alloantibodies. This process is clinically significant in several contexts:

1. **Pregnancy (Rh/RBC alloimmunization)**: When an Rh(D)-negative mother is exposed to Rh(D)-positive fetal red blood cells (via placental hemorrhage, trauma, delivery, or invasive procedures), she can develop anti-D IgG antibodies. In subsequent pregnancies with an Rh(D)-positive fetus, these IgG antibodies cross the placenta and cause hemolytic disease of the fetus and newborn (HDFN), leading to fetal anemia, hydrops fetalis, and kernicterus. Prevention involves administration of Rho(D) immune globulin (RhoGAM) at 28 weeks gestation and within 72 hours postpartum (or after sensitizing events) to prevent maternal antibody formation. Other RBC antigens (Kell, Duffy, Kidd) can also cause alloimmunization and HDFN, though less commonly than Rh(D).

2. **Transfusion medicine**: Repeated blood transfusions can lead to alloimmunization against minor RBC antigens, platelet antigens (HPA), or HLA antigens, causing delayed hemolytic transfusion reactions, platelet refractoriness, or difficulty finding compatible blood products. This is particularly problematic in patients with sickle cell disease or thalassemia requiring chronic transfusions.

3. **Solid organ and hematopoietic stem cell transplantation**: Alloimmunization against donor HLA antigens is a major cause of graft rejection. Pre-formed antibodies (from prior transfusions, pregnancies, or transplants) can cause hyperacute or acute antibody-mediated rejection. Panel reactive antibody (PRA) testing and crossmatching are used to assess alloimmunization risk before transplantation.

4. **Pathophysiology**: Alloantigens are recognized by the recipient's immune system as foreign, triggering B-cell activation (often with T-cell help) and antibody production. Memory B cells persist, leading to more rapid and robust antibody responses upon re-exposure (anamnestic response), which is why first exposures are often subclinical but subsequent exposures are more dangerous.

5. **Clinical testing**: Indirect Coombs test (indirect antiglobulin test) detects alloantibodies in maternal or recipient serum before transfusion/pregnancy complications arise. Direct Coombs test (direct antiglobulin test) detects antibodies already bound to RBCs in the fetus/newborn or transfusion recipient.

High-yield board associations: Rh(D) alloimmunization and HDFN, RhoGAM mechanism and timing, Kell antigen causing more severe anemia due to suppression of erythropoiesis (not just hemolysis), and alloimmunization in sickle cell patients complicating transfusion therapy.